UnitedHealth posts $5.5B profit in Q2

By Jakob Emerson – UnitedHealth Group posted nearly $5.5 billion in profit for the second quarter of 2026, up sharply from the same period last year. The company released second-quarter earnings July 16, raising its full-year outlook to a range of $18.45 to $18.95 per share, with adjusted earnings of $19.50 to $20.00 per share. Read Full Article...

HVBA Article Summary

1. Stronger profitability and margin expansion: UnitedHealth reported $112 billion in quarterly revenue, roughly flat year over year, while improving its consolidated operating margin to 7.1% from 4.6% a year earlier. The company’s medical cost ratio declined to 86.7%, down 270 basis points from the prior year quarter, signaling improved cost performance. Days claims payable were 47, compared to 48.6 in the prior quarter and 44.5 a year ago, reflecting shifts in payment timing. Together, these metrics indicate tighter cost controls and improved operating efficiency despite stable top-line growth.

2. UnitedHealthcare earnings surge amid cost pressures: The insurance segment generated $86 billion in revenue, approximately flat year over year, but delivered a 90% increase in operating earnings to $3.9 billion. Operating margin improved to 4.6% from 2.4% in the same quarter last year, driven by pricing discipline, benefit design changes and medical cost management. Executives noted that commercial medical cost trends are running modestly above 11%, with margin recovery expected to extend beyond 2027. Leadership attributed ongoing pressure in part to the No Surprises Act arbitration process and increased provider coding intensity.

3. Mixed performance across Optum businesses: Optum’s overall revenue declined 2% year over year to $65.7 billion, even as operating earnings rose 32% to $4 billion and margin expanded to 6.2%. Optum Health revenue fell 5% due to about 700,000 fewer value-based care patients, though its operating earnings more than doubled year over year. Optum Rx posted a slight revenue decline but a 7% increase in operating income, while Optum Insight grew revenue 3% and increased operating earnings 14%. The results show divergent trends across service lines, with profitability gains offsetting softer revenue in certain segments.

Mid-year benefits review: What employers miss before renewal

By Charlene Zielinski – Mid-year is one of the most misleading periods in employee benefits planning. Claims appear stable, renewal is still months away and many employers assume their health plan is tracking as expected. Yet some of the most significant cost drivers emerge during the second half of the year, often after key strategic decisions should already have been made. Read Full Article...

HVBA Article Summary

1. Mid-Year Stability Can Mask Emerging Risk: Employers often interpret flat spending in the first half of the year as a sign that their plan is on track, but claims data is backward-looking and incomplete. Incurred but unreported claims and newly developing utilization patterns may not yet appear in reports. Cost pressures from large claimants or new treatments frequently materialize later in the year. Relying solely on early-year data can leave organizations unprepared for renewal discussions.

2. Specialty Pharmacy and Behavioral Health Are Key Volatility Drivers: Specialty medications can add hundreds of thousands of dollars in annual expenses for a single claimant, especially if treatment begins mid-year. At the same time, behavioral health utilization continues to rise, affecting both plan costs and workforce productivity. Outpatient procedures and increased referral patterns can also quietly build financial pressure through higher frequency of services. Together, these areas represent evolving risks that require closer monitoring than many employers currently apply.

3. Proactive Mid-Year Reviews Expand Strategic Options: Conducting deeper claims and utilization analyses mid-year allows employers to assess stop-loss exposure, vendor performance and care management engagement before renewal pressure sets in. Early review creates time to consider alternative funding arrangements, refine pharmacy strategies or strengthen clinical oversight. Brokers and third-party administrators can add value by interpreting trend data and identifying intervention opportunities. Organizations that treat benefits management as an ongoing process rather than an annual event tend to have more flexibility and better outcomes at renewal.

Healthcare Groups Praise Unanimous Committee Approval of MA Prior Auth Bill

By Marissa Plescia – The Improving Seniors’ Timely Access to Care Act passed out of the House Ways and Means Committee unanimously on Wednesday, a move that many healthcare advocates are applauding. Read Full Article...

HVBA Article Summary

1. Bipartisan Momentum for Prior Authorization Reform: The bill was introduced by a bipartisan group of House lawmakers, with a companion measure introduced in the Senate. It advanced through the House Ways and Means Committee on a 42-0 vote, signaling broad political support. The legislation now heads to the House Energy and Commerce Committee for further consideration. This level of consensus suggests lawmakers from both parties view Medicare Advantage prior authorization as an area in need of reform.

2. New Requirements for Medicare Advantage Plans: The legislation would set clear timeframes for prior authorization decisions, requiring standard requests to be completed within seven days and urgent requests within 72 hours. It also mandates a transition to electronic prior authorization processes and requires public reporting of prior authorization data. In addition, the Centers for Medicare & Medicaid Services would be tasked with assessing real-time authorization processes. These changes are intended to improve transparency and reduce administrative delays affecting seniors.

3. Strong Support from Healthcare Organizations: Major healthcare groups, including the American Health Care Association, the American Medical Association and the American Hospital Association, voiced support for the bill’s advancement. Advocates argue that current prior authorization practices can delay necessary care, particularly for seniors needing post-acute services. However, the hospital association urged lawmakers to reinstate an earlier 2028 deadline for electronic prior authorization adoption instead of the revised 2029 date. The committee also advanced other healthcare measures focused on rural access and reimbursement during the same session.

ELEVANCE 2Q26 EARNINGS ANALYSIS: The Company Beat Wall Street’s Estimates. Investors Punished It Anyway. Here’s Why.

By Wendell Potter – Elevance Health, the giant health insurance conglomerate that operates Blue Cross plans in 14 states under the Anthem brand, reported second-quarter profits yesterday that blew past Wall Street’s expectations. The company reported adjusted earnings per share of $7.45, well above Wall Street financial analysts’ consensus estimate of $6.21. Revenue growth also exceeded expectations and the company raised its full-year 2026 earnings guidance to at least $27 a share. Read Full Article...

HVBA Article Summary

1. Investment Gains Masked Core Weakness: Although Elevance surpassed earnings expectations, a significant portion of the upside came from a sharp increase in investment income rather than improvements in its insurance operations. Investment income rose 44.9% year over year to $704 million, while operating gain from running its health plans fell nearly 28% to $1.8 billion. In its core Health Benefits segment, operating gain dropped 42.6%, signaling pressure in the company’s primary business. This divergence suggests that the headline earnings beat did not reflect stronger underlying insurance performance.

2. Higher Medical Costs and Payment Timing Affected Results: The company’s medical loss ratio increased to 89.7%, indicating it spent a larger share of premium dollars on medical claims compared to the prior year. Elevance also reported “days in claims payable” rising to 45.4 days, meaning it held onto funds longer before paying providers. While executives described their reserving practices as consistent, holding claims longer can temporarily improve cash flow and earnings presentation. Together, these trends contributed to investor concerns about cost pressures and sustainability.

3. Membership Declines Concentrated in Government Programs: Despite revenue rising to $100.7 billion in the first half of the year, total medical membership fell 1.5% to 44.9 million. Medicare Advantage enrollment dropped 15.9% year over year, Medicaid membership declined 4.3%, and ACA marketplace enrollment fell 7.5% from the prior quarter. Executives said the company plans to exit certain Medicaid markets where returns are not deemed sustainable, including the District of Columbia. These enrollment losses, particularly in government-funded programs, weighed on investor sentiment despite overall revenue growth.

Employers push health savings plans, nutritional counseling to avoid GLP-1 coverage for weight loss

By Ginger Christ – As employers grapple with worker demand for GLP-1 drugs for weight loss, 1 in 5 employers recommend employees use their FSA, HSA or integrated HRA to acquire them, according to new research from the International Foundation of Employee Benefit Plans. Read Full Article...

HVBA Article Summary

1. Limited Employer Coverage Amid Growing Demand: Only 36% of employers currently cover GLP-1 medications for weight loss, and just 9% of those that do not offer coverage are considering adding it. This restrained approach comes even as employee interest continues to rise. Employers appear cautious about expanding benefits despite increasing public awareness and usage. The data suggests a significant gap between worker demand and employer-sponsored coverage.

2. Costs Are Driving Benefit Strategy Decisions: GLP-1 drugs accounted for 11.4% of annual corporate claims in 2025, up from 6.9% in 2023. That rapid increase has made the medications a substantial line item in employer health spending. As a result, many organizations are steering workers toward tax-advantaged accounts like FSAs and HSAs instead of adding direct coverage. Employers are also leaning on alternative benefits to help manage both demand and financial exposure.

3. Usage Trends and Broader Health Impacts: Gallup found that 11% of U.S. adults surveyed said they currently use GLP-1 medications for weight loss, nearly four times the share reported two years earlier. Overall, 15% said they have used the drugs at some point, reflecting a sharp rise in adoption. During the same period, the national adult obesity rate declined from 39.9% in 2022 to 36.4% in 2026, a drop Gallup linked to increased GLP-1 use. Separate research from Aon also indicated that medical cost growth was three percentage points lower over 18 months for GLP-1 users, suggesting potential longer-term cost implications for employers.

CVS Caremark, FTC settle anticompetitive practices lawsuit

By Alan Goforth – CVS Caremark has reached a global settlement with the Federal Trade Commission that resolves all outstanding FTC litigation and investigations related to CVS Health that involve rebate, pharmacy network contracting and vertical integration issues. In a lawsuit filed in September 2024, the FTC alleged that CVS Caremark, along with Express Scripts and OptumRx, used rebate systems that favored higher-cost drugs, driving up list prices and out-of-pocket costs for patients. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Settlement Resolves Broad FTC Allegations: The agreement ends multiple FTC legal actions and investigations concerning CVS Health’s pharmacy benefit management practices. Regulators had accused the company and other major PBMs of structuring rebate arrangements in ways that incentivized higher-priced medications. By reaching a global settlement, CVS Caremark avoids continued litigation and commits to changes aimed at addressing competition and pricing concerns. The company said the resolution eliminates the need for further courtroom proceedings tied to these matters.

2. Operational Changes Target Pricing and Transparency: Under the settlement, CVS Caremark will adjust how member cost-sharing is calculated so it more closely reflects net drug costs after rebates. The company also plans to move away from certain rebate guarantees and spread pricing, while expanding reporting on drug pricing, rebates and broker compensation. Additional steps include promoting point-of-sale rebate passthrough and delinking manufacturer compensation from list prices. These measures are intended to simplify pricing structures and make cost flows clearer to plan sponsors and members.

3. Expanded Affordability Programs and Pharmacy Reimbursement Updates: CVS Caremark will broaden affordability initiatives, including capping insulin costs at $25 per month and counting certain prescription purchases toward deductibles and out-of-pocket maximums where permitted. The company will also transition to acquisition-based reimbursement for independent retail pharmacies to better align payments with pharmacies’ actual costs. Many of these commitments build on existing programs such as flat-dollar copays, preventive drug lists and its TrueCost pricing model. CVS Caremark said it will implement the changes according to timelines established with the FTC while continuing to work with regulators and employers.

The hidden cost of healthcare: When affording care means putting life on hold

By Teira Gunlock – A recent West Health-Gallup survey found that one-third of American adults — roughly 82 million people — are making quiet, daily tradeoffs in order to afford healthcare. One in ten are skipping meals or driving less to save on gas, while one in five are postponing larger ambitions, like changing jobs. Read Full Article... ^{_{(Subscription required)}}

HVBA Article Summary

1. Healthcare Costs Are Reshaping Major Life Decisions: Beyond daily budgeting tradeoffs, rising healthcare expenses are influencing long-term milestones. The article notes that 14% of people report delaying buying a home and 6% are postponing expanding their families due to cost pressures. These outcomes are not traditionally categorized as healthcare metrics, yet they are increasingly tied to affordability challenges. This suggests healthcare costs are affecting broader economic mobility and personal planning.

2. Delayed Care Leads to Higher Downstream Costs: When individuals struggle to afford or access care, treatment is often postponed or skipped entirely. This can allow manageable or chronic conditions to worsen, eventually requiring more intensive and expensive interventions. The article argues that these deferred costs ultimately resurface for employers through higher claims and more serious health issues. Preventive opportunities are missed, increasing long-term financial and health consequences.

3. Complexity and Financial Stress Undermine Workplace Productivity: Financial strain related to healthcare extends into the workplace through distraction and disengagement. Over half of employees experiencing financial stress report spending three or more hours each week at work dealing with personal finance concerns. The author contends that simply adding more benefit offerings is not enough if employees find them confusing or difficult to navigate. Simplifying access and reducing administrative burden are presented as key strategies to improve both health outcomes and workforce performance.